Lebrikizumab is primarily used in the treatment of moderate to severe atopic dermatitis. It works by targeting and inhibiting interleukin-13 (IL-13), a key cytokine involved in the inflammatory pathways that drive skin barrier dysfunction and itching in atopic dermatitis. By blocking IL-13, lebrikizumab helps reduce inflammation, improve skin clarity, and relieve symptoms such as pruritus (itching). It is also being investigated for use in other Th2-mediated conditions, including asthma and chronic rhinosinusitis with nasal polyps, where IL-13 plays a central role in disease pathology. In clinical trials, patients treated with lebrikizumab have shown significant improvement in eczema severity and quality of life measures compared to placebo. The antibody is administered via subcutaneous injection and is designed for patients who do not respond adequately to topical therapies or require systemic treatment. Its targeted mechanism offers a favorable safety profile with fewer broad immunosuppressive effects compared to older systemic agents.